The privately held Cambridge, UK-based company announced earlier this month that it had raised an additional £11 million to support the commercialization of its platform.

Funds will support projects aimed at earlier identification of patients who can benefit from treatment.

GSK will use the Breath Biopsy to assess whether the right treatment for the right patient can be identified, and to evaluate its drug candidate for COPD.

Among people with a wheeze, the test people can identify people with asthma, but among the asymptomatic public, it is better at identifying people who don't have asthma.